Turalio

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

1 competitor in Tenosynovial Giant Cell Tumor

#DrugCompanyPhaseTrials

1

Turalio

Daiichi Sankyo

Phase 3

22

Pimicotinib

AAbbisko Therapeutics Co, Ltd

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tics2 trials

Effect of Probenecid on Pexidartinib Pharmacokinetics

Completed·Daiichi Sankyo·Phase 1·NCT03138759·16 enrolled

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Completed·Daiichi Sankyo·Phase 1·NCT03291288·32 enrolled

Advanced Solid Tumors2 trials

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Completed·Daiichi Sankyo·Phase 1·NCT02734433·12 enrolled

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Completed·CCogent Biosciences, Inc.·Phase 1/2·NCT02401815·51 enrolled

Giant Cell Tumor2 trials

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

Completed·Daiichi Sankyo·Phase 4·NCT04526704·32 enrolled

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Completed·Daiichi Sankyo·Phase 3·NCT02371369·120 enrolled

Tenosynovial Giant Cell Tumor2 trials

Multicenter, Single Arm Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor

Active, not recruiting·Daiichi Sankyo·Phase 3·NCT04488822·40 enrolled

A Phase 2, Multicenter, Two-Part, Open-Label Study of Pexidartinib in Adult Subjects With Tenosynovial Giant Cell Tumor in Japan

Completed·Daiichi Sankyo·Phase 2·NCT04703322·9 enrolled

Colorectal Cancer1 trial

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

Completed·CCentre Leon Berard·Phase 1·NCT02777710·48 enrolled

2 more indications

Moderate Hepatic Impairment1 trial

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Completed·Daiichi Sankyo·Phase 1·NCT04223635·16 enrolled

Gastrointestinal Stromal Tumor1 trial

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03158103·3 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Patent Landscape[5]

Related News